PBS Biotech Launches Breakthrough MiniPRO™ Multi-Parallel Bioreactor Platform for Cell Therapy Process Development
PBS Biotech has unveiled MiniPRO™, a new multi-parallel Vertical-Wheel® bioreactor platform designed to accelerate high-throughput cell therapy process development.
The platform will be showcased at the ISSCR PSC-Derived Therapies Symposium in Boston this December.
MiniPRO™ enables researchers to run up to 24 independent, small-scale cultures simultaneously within an automated, closed system.
It provides real-time monitoring and control of temperature, agitation, oxygenation, and pH, as well as perfusion media exchange.
These capabilities allow scientists to streamline early-stage process development, reduce development time and costs, and create robust, scalable manufacturing processes—key challenges in the rapidly growing cell therapy field.
Built on PBS Biotech’s patented Vertical-Wheel® technology, already used in larger GMP-ready bioreactors, MiniPRO™ replicates the same fluid dynamics and performance at a miniature scale.
This ensures that lab-developed processes can be confidently scaled to clinical manufacturing. Early customer and partner feedback has been positive, highlighting the platform’s ability to bridge the gap between R&D and clinical production.
At the ISSCR Symposium, attendees will have the opportunity to view MiniPRO™ firsthand during an Innovation Showcase hosted by PBS Biotech’s Director of Product Management & Strategy, Sharon Harvey.
The company is supported by investors including Avego, a healthcare-focused investment firm, and BroadOak, a life sciences-focused boutique financial institution.
